The industry might agree to savings in 2020 to bolster those negotiated in 2017, only to confront a new round of requests in 2022 or 2023. Any extension in 2020 will mean the industry just pays again for the 'certainty' it already has until mid-2022. …
The price of paying twice or three times for the same 'certainty'
September 14, 2020 CommentLatest News
Latest Video
Georgia Forrest
New Stories
-
Australian medtech secures funds to advance real-time breast cancer surgery technology
February 13, 2026 - - Australian Biotech -
The Dispatched Podcast 'Week in Review' - 13 February
February 13, 2026 - - Podcast -
PBAC to reconsider broader vaccine funding after late addition to March agenda
February 13, 2026 - - Latest News -
Ten years of process 'improvements' is almost the point, says Anne Ruston
February 13, 2026 - - Latest News -
Senate scrutiny of PBS rules after Canberra family highlights lack of biologic access
February 12, 2026 - - Latest News -
There is no negotiation, yet, so be careful not to give the impression of conceding anything
February 11, 2026 - - Latest News -
Arrotex and Pfizer forge strategic pharmacy partnership for ENBREL in Australia
February 11, 2026 - - Latest News